At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)drug
Likely dose
tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo) 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (IVH)
In Brief
A Phase 2 clinical trial evaluating tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo) for Intraventricular Hemorrhage. Completed, enrolled 52 participants across 25 sites in 4 countries.
Detailed Summary
The specific objective of this trial is to determine the lowest dose and dose frequency possible with the best pharmacokinetic and safety profile and it's ability to remove a blood clot from the ventricular system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraventricular Hemorrhage
CountriesCanada, Germany, United Kingdom, United States
CollaboratorsFDA Office of Orphan Products Development, Genentech, Inc.
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
First PostedApr 2008
Primary CompletionAug 2008
TodayJul 2026
First PostedApr 2, 2008
Enrollment StartFeb 1, 2004
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.3 years ago
Interventions
tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)drug
0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.